Pasithea Therapeutics (US:KTTA) Globenewswire·2025-11-25 12:00Core Insights - The ALS Association has awarded Pasithea Therapeutics a grant of approximately $1 million to study PAS-004 in ALS patients, focusing on its efficacy, safety, and tolerability [1][2] - This grant marks the initiation of the first clinical trial of PAS-004 in individuals with ALS, which is a significant milestone for the company [2] - PAS-004 is a next-generation macrocyclic MEK inhibitor that has shown promising results in preclinical models and is currently being tested in other clinical trials for different conditions [2][3] Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on developing PAS-004 for various diseases, including ALS, RASopathies, and MAPK pathway-driven tumors [3] - The company is conducting a Phase 1 clinical trial of PAS-004 in advanced cancer patients and a Phase 1/1b trial in patients with neurofibromatosis type 1 [3] ALS Association Overview - The ALS Association is the largest organization dedicated to ALS, funding research, providing support to patients and families, and advocating for better public policies [4] - The association's mission is to make ALS livable and ultimately find a cure for the disease [4] Disease Context - Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that leads to loss of motor function and is typically fatal within five years of diagnosis [5] - There is a significant unmet need for new therapies to address the functional deficits and progression of ALS [5]